AFASCI, INC.
AFA-281, a small-molecule dual inhibitor of T-type calcium channels (Cav3) and soluble epoxide hydrolase (sEH) for treatment of cocaine use disorder
- Sector
- Biotech
- Headquarters
- Redwood City, CA
- Total capital
- $15.6M
- Federal grants
- $15.2M
- 19 awards · 2015–2025
- Rank in peer group#19 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $339K
- 1 award · Health and Human S
- Rank in Biotech#252 of 4373
- Granted patents
- 3
- 4 pending · first 2019
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Accelerating the non-opioid analgesic AFA-281 clinical development with TABA-supported business development$50K
- Federal grantHealth and Human S · Phase II · Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain$1.5M
- Federal grantHealth and Human S · Phase I · Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase$320K
- Federal grantHealth and Human S · Phase II · Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain$1.5M
- Federal grantHealth and Human S · Phase II · IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain$1.5M
- Federal grantHealth and Human S · Phase II · Development of a Next Generation Visual Performance Assessment System for Rodents$692K
- Federal grantHealth and Human S · Phase I · Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic$100K
Show 13 earlier federal awards
- Federal grantHealth and Human S · Phase I · Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic$150K
- Federal grantHealth and Human S · Phase II · Development of a Next Generation Visual Performance Assessment System for Rodents$788K
- Federal grantHealth and Human S · Phase II · IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain$3M
- Federal grantHealth and Human S · Phase II · Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease$241K
- Federal grantHealth and Human S · Phase I · Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic$150K
- Federal grantHealth and Human S · Phase II · Development of patented tricyclic pyrones molecules for the treatment of Alzheimer’s Disease$961K
- Federal grantHealth and Human S · Phase II · Development of patented tricyclic pyrones molecules for the treatment of Alzheimer's Disease$2.2M
- Federal grantHealth and Human S · Phase I · Sample-free onsite detection of cocaine using microneedles via laser-treated skin$224K
- Federal grantHealth and Human S · Phase II · Development of selective Cav3 channel blockers for treatment of neuropathic pain$742K
- Federal grantHealth and Human S · Phase I · Developing a novel CGRP antagonist for treatment of dental neuroinflammatory pain$222K
- Federal grantHealth and Human S · Phase II · Development of selective Cav3 channel blockers for treatment of neuropathic pain$691K
- Federal grantHealth and Human S · Phase I · A Visual Assessment System for Retinal Function/Drug Discovery$233K
- Federal contractHealth and Human S · Igf::ot::igf: FY13: "phenotypic Screening Of Smoking Cessation Drugs," N43DA-13-7786: Purpose: To Fund Base Award Of SBIR Phase I Contract; Pop: 8/30/2013 - 8/29/2014.$339K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#19 · top 4%
- Granted patents#109 · top 21%
- Linked publications#37 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 3 granted of 7- PendingMethods Of Treating Hypersensitive Cough Or Itching Using Ion Channel Inhibitory CompoundsUSPTOApplication 18460648
- GrantedMethods Of Treating Hypersensitive Cough Or Itching Using Ion Channel Inhibitory CompoundsUSPTOUS 11,744,825
- GrantedIon Channel Inhibitory Compounds, Pharmaceutical Formulations, and UsesUSPTOUS 10,562,857
Show all 7 patent records
- Methods Of Treating Hypersensitive Cough Or Itching Using Ion Channel Inhibitory CompoundsDec 28, 2023 · Application 18460648Pending
- Methods Of Treating Hypersensitive Cough Or Itching Using Ion Channel Inhibitory CompoundsSep 5, 2023 · US 11,744,825Granted
- Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and UsesFeb 18, 2020 · US 10,562,857Granted
- Compositions And Methods For Treating Acute And Chronic Pain By Local Antagonism Of Cgrp Receptors, Or Combination With Sodium Channel Inhibition Or With Anti-inflammatory AgentsMay 14, 2019 · US 10,287,337Granted
- Methods Of Treating Hypersensitive Cough Or Itching Using Ion Channel Inhibitory CompoundsApplication PCTUS2019048666Pending
- Ion Channel Inhibitory Compounds, Pharmaceutical Formulations And UsesApplication PCTUS2016061918Pending
- Ion Channel Inhibitory Compounds, Pharmaceutical Compositions And UsesApplication 62254564Pending
Recent research by its founders
- Targeting iron-associated protein Ftl1 in the brain of old mice improves age-related cognitive impairment202511 cites
- From Dream-Making Machine to Dream-Crafting Intelligence:On the Ethics of Film and Television Creation Driven by Generative AI20250 cites
- Sexual Arousal, Role of Histamine and Orexin/Hypocretin Neurons20250 cites
Related companies, and why
- MATRISOME BIO, INC.Similar federal contract value in Biotech · $354K in contracts
- Longevity Biotech, IncSimilar federal contract value in Biotech · $348K in contracts
- GENOMIC EXPRESSION INCSimilar federal contract value in Biotech · $340K in contracts
- Telesis Bio Inc.Similar federal contract value in Biotech · $337K in contracts
- QUALITY BIOLOGICAL, INC.Similar federal contract value in Biotech · $336K in contracts
- NAPO PHARMACEUTICALS INCSimilar federal contract value in Biotech · $335K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .